Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.

Promising red-light myopia treatment for children is raising safety concerns among experts

Myopia, or near-sightedness, is on the rise: Nearly half of the world’s population will be nearsighted by 2050, according to the World Health Organization. The condition

February 2, 2024

Identifying genetic resistance factors and antimicrobial resistance phenotypes in MRSA strains

With the rising prevalence of methicillin-resistant Staphylococcus (S.) aureus (MRSA), a multi drug resistant strain, treatment has become a challenge.

March 18, 2025

AstraZeneca, Daiichi Sankyo claim PhIII lung cancer win for their next big ADC — but shares fall

AstraZeneca and Daiichi Sankyo’s multibillion-dollar antibody-drug conjugate alliance has generated a Phase III win, the partners say, beefing up the case that they have a

July 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.